Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY

Next Previous
Trial Profile

A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Methylprednisolone; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Pharmacodynamics; Registrational
  • Acronyms STAAR
  • Sponsors Churchill Pharmaceuticals; Sun Pharma Global FZE

    • Most Recent Events

    • 23 May 2018 According to a Sun Pharmaceutical Industries media release, based on the data of this study, the U.S. Food and Drug Administration has approved YONSA (abiraterone acetate), a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
    • 10 Feb 2018 Results of subgroup analysis assessing pharmacokinetic parameters presented at the 2018 Genitourinary Cancers Symposium.
    • 06 Feb 2018 According to a Churchill Pharmaceuticals media release, the results of the study will be presented at the 2018 American Society of Clinical Oncology, Genitourinary Cancers Symposium (ASCO GU).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top